SAN DIEGO -- AXS-12 (reboxetine), an investigational treatment for narcolepsy, reduced weekly cataplexy attacks and in some cases provided complete remission, the phase III SYMPHONY study showed. From ...
AXS-12 reduced the frequency of cataplexy attacks per week compared with placebo (P =.017). Topline results were announced from a phase 3 trial evaluating AXS-12 (reboxetine) in patients with ...
Pitolisant is now the only treatment option not scheduled as a controlled substance that is indicated for both excessive daytime sleepiness and cataplexy in pediatric and adult patients. The Food and ...
On Tuesday, Axsome Therapeutics Inc (NASDAQ:AXSM) said AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) in Phase 3 ENCORE ...
Narcolepsy with cataplexy, now known as type 1 narcolepsy, is a chronic neurological disorder that affects a person’s sleep-wake cycle and involves muscle weakness. The condition can cause a person to ...
Add Yahoo as a preferred source to see more of our stories on Google. Common symptoms of narcolepsy, including excessive daytime sleepiness, cataplexy (sudden loss of motor strength and tone), ...
Exercise can feel complicated — or even scary — when you’re living with narcolepsy. Excessive daytime sleepiness, disrupted nighttime sleep, brain fog, and sudden muscle weakness can make it harder to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results